| Identification | Back Directory | [Name]
Benzenepropanamide, 4-[(2,6-dichlorophenyl)methoxy]-α-[[1-oxo-3-(2,3,4,5,6-pentafluorophenyl)-2-propen-1-yl]amino]-N-(2,2,6,6-tetramethyl-4-piperidinyl)-, (αS)- | [CAS]
259885-54-6 | [Synonyms]
BKM-570
Benzenepropanamide, 4-[(2,6-dichlorophenyl)methoxy]-α-[[1-oxo-3-(2,3,4,5,6-pentafluorophenyl)-2-propen-1-yl]amino]-N-(2,2,6,6-tetramethyl-4-piperidinyl)-, (αS)- | [Molecular Formula]
C34H34Cl2F5N3O3 | [MOL File]
259885-54-6.mol | [Molecular Weight]
698.56 |
| Hazard Information | Back Directory | [Description]
BKM-570 is a bradykinin antagonist, causing impressive growth inhibition of lung and prostate tumors, displaying superior in vivo inhibitory effects than convential chemotherapeutic drugs. | [Uses]
BKM-570 is a nonpeptide bradykinin antagonist with anticancer effects. BKM-570 can be used in the study of lung cancer, prostate cancer and ovarian cancer[1]. | [References]
[1] Stephanie Jutras, et al. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action. FEBS J. 2010 Dec;277(24):5146-60. DOI:10.1111/j.1742-4658.2010.07928.x |
|
|